Focus on systemic lupus erythematosus in Indigenous Australians: Towards a better understanding of autoimmune diseases

Internal Medicine Journal

Volumn 43, Issue 3, 2013, Pages 227-234

  Vincent, F B ^a   Bourke, P ^c   Morand, E F ^b   Mackay, F ^a   Bossingham, D ^d  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

Autoimmunity; B cell; B cell activating factor of the tumour necrosis factor (TNF) family (BAFF); Indigenous Australian; Innate immunity; Systemic lupus erythematosus (SLE)

Indexed keywords

AUTOANTIBODY; BELIMUMAB; HLA B27 ANTIGEN; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ALCOHOL CONSUMPTION; ALLERGIC GLOMERULONEPHRITIS; ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; AUSTRALIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BULLOUS PEMPHIGOID; CELL HYPERPLASIA; CROHN DISEASE; DISEASE DURATION; DISEASE SEVERITY; DOMESTIC VIOLENCE; ETHNICITY; GENETIC DIFFERENCE; GENETIC VARIABILITY; GLOMERULONEPHRITIS; HEALTH STATUS; HEART BLOCK; HEMOLYTIC ANEMIA; HEREDITY; HUMAN; INDIGENOUS PEOPLE; INNATE IMMUNITY; LEUKOPENIA; LIFE EXPECTANCY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MOUTH ULCER; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PERINATAL MORTALITY; PHENOTYPE; PHOTOSENSITIVITY; PLASMACYTOID DENDRITIC CELL; POLYARTHRITIS; POPULATION GENETICS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RASH; REVIEW; RHEUMATIC HEART DISEASE; RHEUMATOID ARTHRITIS; SCLEROSIS; SKIN INFECTION; SMOKING; SPONDYLITIS; SPONDYLOARTHROPATHY; SUBSTANCE ABUSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION;

AUSTRALIA; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; OCEANIC ANCESTRY GROUP;

EID: 84874371515     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12039     Document Type: Review

References (72)

1. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006; 45: 187-191.
2. Jacobsson LT, Hanson RL, Knowler WC, Pillemer S, Pettitt DJ, McCance DR etal. Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum 1994; 37: 1158-1165.
3. Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjogren's syndrome: where are we now? Clin Exp Rheumatol 2007; 25: 1-4.
4. Goransson LG, Haldorsen K, Brun JG, Harboe E, Jonsson MV, Skarstein K etal. The point prevalence of clinically relevant primary Sjogren's syndrome in two Norwegian counties. Scand J Rheumatol 2011; 40: 221-224.
5. Zurauskas J, Beroukas D, Walker JG, Smith MD, Ahern MJ, Roberts-Thomson PJ. Scleroderma in Australian Aborigines. Intern Med J 2005; 35: 60-62.
6. Vincent FB, Morand EF, Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol 2012; 90: 293-303.
7. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56: 2092-2094.
8. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38: 551-558.
9. Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol 1993; 32: 110-115.
10. Ong C, Nicholls K, Becker G. Ethnicity and lupus nephritis: an Australian single centre study. Intern Med J 2011; 41: 270-278.
11. Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol 2000; 27: 1884-1891.
12. Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian Aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993; 23: 646-651.
13. Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus 2003; 12: 327-331.
14. Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian Aboriginals. Aust N Z J Med 1995; 25: 182-183.
15. Segasothy M, Phillips PA. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study. Lupus 2001; 10: 439-444.
16. Bloor G, Rigby RJ, Richmond JM, Zilko PJ, Dawkins RL. Systemic lupus erythematosus in Australian Aborigines. Aust N Z J Med 1982; 12: 553.
17. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 116-119.
18. Alarcon GS, Bastian HM, Beasley TM, Roseman JM, Tan FK, Fessler BJ etal. Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement. Lupus 2006; 15: 26-31.
19. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
20. Boers A, Li Q, Wong M, Miller M, Littlejohn G. Differences in SLE disease activity between patients of Caucasian and South-East Asian/Chinese background in an Australian hospital. APLAR J Rheumatol 2006; 9: 43-48.
21. Carapetis J, Gardiner D, Currie B, Mathews JD. Multiple strains of Streptococcus pyogenes in skin sores of aboriginal Australians. J Clin Microbiol 1995; 33: 1471-1472.
22. Australian Bureau of Statistics. Experimental Estimates of Aboriginal and Torres Strait Islander Australians. 19/08/2008 ed. Sydney, 2008.
23. AIHW. 2011. Life expectancy and mortality of Aboriginal and Torres Strait Islander people. Cat. no. IHW 51. Canberra: AIHW. [cited 2012 Jul 14]. Available from URL: http://www.aihw.gov.au/publication-detail/?id=10737418927.
24. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-2121.
25. Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011; 13: 250.
26. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
27. Deligny C, Thomas L, Dubreuil F, Theodose C, Garsaud AM, Numeric P etal. Systemic lupus erythematosus in Martinique: an epidemiologic study. Rev Med Interne 2002; 23: 21-29.
28. Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C etal. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol 2009; 36: 1200-1208.
29. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K etal. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69: 1846-1851.
30. McCarty DJ, Manzi S, Medsger TA, Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995; 38: 1260-1270.
31. Stewart JH, McCredie MR, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant 2004; 19: 678-685.
32. Mason JA, Bossingham D. The clinical characterisation of systemic lupus erythematosus in a Far North Queensland Indigenous kindred. Lupus 2009; 18: 144-148.
33. Ranford P, Hay J, Serjeantson SW, Dunckley H. A high frequency of inherited deficiency of complement component C4 in Darwin Aborigines. Aust N Z J Med 1987; 17: 420-423.
34. Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian Aborigines. Aust N Z J Med 1995; 25: 736.
35. Cunningham J. Socioeconomic disparities in self-reported arthritis for Indigenous and non-Indigenous Australians aged 18-64. Int J Public Health 2011; 56: 295-304.
36. Roberts-Thomson PJ, Hedger S, Bossingham D. Rheumatoid arthritis and Australian aboriginals. Med J Aust 1998; 168: 92.
37. Roberts-Thomson RA, Roberts-Thomson PJ. Rheumatic disease and the Australian aborigine. Ann Rheum Dis 1999; 58: 266-270.
38. Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol 2004; 31: 965-972.
39. Lester S, Cassidy S, Humphreys I, Bennett G, Hurley CK, Boettcher B etal. Evolution in HLA-DRB1 and major histocompatibility complex class II haplotypes of Australian aborigines. Definition of a new DRB1 allele and distribution of DRB1 gene frequencies. Hum Immunol 1995; 42: 154-160.
40. Gao X, Serjeantson SW. Diversity in HLA-DR4-related DR, DQ haplotypes in Australia, Oceania, and China. Hum Immunol 1991; 32: 269-276.
41. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995; 7: 263-269.
42. Cleland LG, Hay JAR, Milazzo. SC. Absence of HLA 27 and of ankylosing spondylitis in central Australian Aboriginals. Scand J Rheumatol 1975; 4: 30-35.
43. Chang JH, Raju R, Henderson TR, McCluskey PJ. Incidence and pattern of acute anterior uveitis in Central Australia. Br J Ophthalmol 2010; 94: 154-156.
44. Chang JH, Landers J, Henderson TR, Craig JE. Prevalence of uveitis in indigenous populations presenting to remote clinics of Central Australia. Clin Experiment Ophthalmol 2012; 40: 448-453.
45. Pile KD, Richens JE, Laurent RM, Bhatia K, Prasad ML, Lupiwa T etal. Arthritis in the highlands of Papua New Guinea. Ann Rheum Dis 1993; 52: 49-53.
46. Roberts-Thomson PJ, Roberts-Thomson RA, Nikoloutsopoulos T, Gillis D. Immune dysfunction in Australian Aborigines. Asian Pac J Allergy Immunol 2005; 23: 235-244.
47. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005; 366: 155-168.
48. Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect 2000; 124: 239-244.
49. Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health 2007; 43: 203-213.
50. McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Carapetis JR. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006; 43: 683-689.
51. Steer AC, Carapetis JR. Acute rheumatic fever and rheumatic heart disease in indigenous populations. Pediatr Clin North Am 2009; 56: 1401-1419.
52. Towers RJ, Bolm M, Currie BJ, Chhatwal GS, Fagan PK. Autoantigens identified by screening a human heart cDNA library with acute rheumatic fever sera. Ann N Y Acad Sci 2009; 1173: 83-91.
53. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM etal. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435: 452-458.
54. Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004; 113: 4-13.
55. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ etal. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959-1971.
56. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14: 573-582.
57. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115: 196-202.
58. Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394-399.
59. Ronnblom L. Potential role of IFNalpha in adult lupus. Arthritis Res Ther 2010; 12 (Suppl 1): S3.
60. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM etal. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009; 10: 285-296.
61. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ etal. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-2615.
62. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J etal. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
63. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R etal. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482-487.
64. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I etal. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601-3611.
65. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
66. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P etal. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-829.
67. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
68. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K etal. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
69. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P etal. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
70. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE etal. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
71. Furie R, Petri M, Zamani O, Cervera R, Wallace JD, Tegzova D etal. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
72. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT etal. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178.